Phase 1 Trial Design: Is 3 + 3 the Best?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 1 Trial Design: Is 3 + 3 the Best?

Published:2014-07 Issue:3 Volume:21 Page:200-208
ISSN:1073-2748
Container-title:Cancer Control
language:en
Short-container-title:Cancer Control

Author:

Hansen Aaron R.¹²,Graham Donna M.¹²,Pond Gregory R.³⁴,Siu Lillian L.¹²

Affiliation:

1. Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology

2. Department of Medicine, University of Toronto, Ontario, Canada

3. Department of Oncology, McMaster University

4. Ontario Clinical Oncology Group, Hamilton, Ontario, Canada

Publisher

SAGE Publications

Subject

Oncology,Hematology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/107327481402100304

Reference49 articles.

1. Design and Analysis of Phase I Clinical Trials

2. A Method for Obtaining and Analyzing Sensitivity Data

3. Operating characteristics of the standard phase I clinical trial design

4. Accelerated Titration Designs for Phase I Clinical Trials in Oncology

5. Translation of Innovative Designs Into Phase I Trials

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Personalized Dose‐Finding Algorithm Based on Adaptive Gaussian Process Regression;Pharmaceutical Statistics;2024-08-09

2. Meta‐analyses of phase I dose‐finding studies: Application for the development of protein kinase inhibitors in oncology;Research Synthesis Methods;2024-08-05

3. The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life;JCO Oncology Practice;2024-07

4. Macrophage Therapy for Acute Liver Injury (MAIL): a Phase 1 Randomised, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Activity of Allogeneic Alternatively Activated Macrophages in Patients with Paracetamol-induced Acute Liver Injury;2024-05-28

5. The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies;Clinical Trials;2024-04-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3